Background The antimalarial drug amodiaquine, a commonly used long acting partner drug
in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine …

Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …

Artesunate (AS) is used in combination with amodiaquine (AQ) as first-line treatment for
uncomplicated malaria in many countries. We investigated the effect of concomitant AS …

Abstract CYP2A6, CYP2B6, and UGT1A9 genetic polymorphisms and treatment response
after a three-day course of artesunate-mefloquine was investigated in 71 Burmese patients …

Abstract Background Cytochrome P450 (CYP) enzymes are essential in the metabolism of
most drugs used today. Single nucleotide polymorphism (s) occurring in CYP genes can …

The human Cytochrome (cyp2C8) and N-acetyltransferase II (nat2) genes may vary between
individuals resulting in differences in anti-plasmodial treatment responses. We set out in this …

Aims We assessed the disposition of oral amodiaquine (AQ) and CYP2C8 polymorphism in
20 children with falciparum malaria. Methods AQ and DEAQ concentrations were …

Background Sub-Saharan Africa (SSA) population is genetically diverse and heterogenous
thus variability in drug response among individuals is predicted to be high. Cytochrome …

Background Artemisinin-based combinations currently recommended for treatment of
uncomplicated Plasmodium falciparum malaria in many countries of sub-Saharan Africa are …

Background CYP2C8 polymorphisms can impair the metabolism of the antimalarial
amodiaquine and influence exposure to the key active metabolite desethylamodiaquine …